Oral Drug Delivery Patents: Leaders, Trends & White Space 2026
- Concentration is modest at the top. the leading assignee holds 820 records but the top 5 combined account for only 15.0% of the 20,627 records in scope — no single filer controls the field.
- Filings peaked in 2019 at 939 and 2021-to-2024 volume fell 46% (772 to 414), though 2025-26 figures are still filling in under the usual 18-month publication lag.
- A61K medicinal preparations dominate the class mix at 80.8% of records, while device-side classes like A61M sit at just 3.2%, marking where formulation claims crowd out delivery-hardware claims.
Filing growth compares 2021 (772 records) with 2024 (414) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 20,627 records in scope (CR5), not by the ranked leaders only.
What the oral drug delivery patent record actually shows
Oral drug delivery spans formulation chemistry, controlled-release engineering and the biologics that increasingly need to survive the gut to work at all. The 20,627 records in this dataset run from 2015 through the 2026 cut-off, capturing everything from osmotic dispensing devices to targeted binding agents formulated for oral administration. Patent families, not raw document counts, are the fairer read on activity here, since continuation practice and multi-jurisdiction filing inflate document totals without adding new invention.
Filing activity rose to a peak in 2019 and has since pulled back, a pattern consistent with a field that filled in its core formulation claims early and is now filing more selectively into specific mechanisms and combinations.
Filing trends and technology composition
Two views of the same 20,627-record corpus: how volume has moved year over year, and how records distribute across IPC subclasses.
Filings rose to a 2019 peak, then pulled back
Annual filings ran from 875 in 2017 to a peak of 939 in 2019. The 2021-to-2024 span shows a 46% decline, from 772 to 414 records; 2025 and 2026 figures will rise as later publications catch up, per the standard 18-month lag between filing and publication.
Formulation chemistry dominates the class mix
A61K (medicinal preparations) appears on 80.8% of the 20,627 records, far ahead of A61P therapeutic-activity classifications at 38.5%. Heterocyclic compounds (C07D, 18.9%) and peptides/proteins (C07K, 18.7%) run close together, while device-oriented A61M sits at just 3.2%, and material-analysis class G01N at 3.5% — both comparatively thin given how central testing and delivery hardware are to getting an oral biologic to market.
Shares are the percentage of the 20,627 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Oral Drug Delivery Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about oral drug delivery patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe documents shaping freedom-to-operate
US20080213381A1 — Oral Drug Delivery System
A coated-tablet system combining an active-ingredient core with a coating layer built from a water-insoluble polymer and a pH-dependent polymer, engineered so the coating reliably breaks down after a predetermined delay to release the active ingredient at a targeted point in the gastrointestinal tract.Filed by Sun Pharma Advanced Research Company Limited, published 2008-09-04.
View full filing| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US3916899A | Osmotic dispensing device with maximum and minimum sizes for the passageway | 5,840 |
| 2 | WO2011066389A1 | Targeted binding agents against b7-h1 | 1,789 |
| 3 | US5444113A | End use applications of biodegradable polymers | 1,616 |
| 4 | WO1996020698A2 | Surface-modified nanoparticles and method of making and using same | 1,409 |
| 5 | US6660843B1 | Modified peptides as therapeutic agents | 1,126 |
| 6 | US6060082A | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery | 1,056 |
| 7 | US6004534A | Targeted polymerized liposomes for improved drug delivery | 1,048 |
| 8 | US5490962A | Preparation of medical devices by solid free-form fabrication methods | 929 |
| 9 | US8779108B2 | Targeted binding agents against B7-H1 | 924 |
| 10 | US20130034559A1 | Targeted Binding Agents Against B7-H1 | 882 |
Citation counts favour older filings simply because they've had longer to accumulate citations inside this corpus — read them as a signal of influence on the field, not as evidence that a document remains current or unchallenged.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the filing data signals
Three read-throughs on the numbers that matter for a filing or freedom-to-operate decision.
No single company controls oral delivery claims
The leading assignee holds 820 records against a field of 20,627, and the top 5 combined reach only 15.0% of all records in scope. That is a fragmented field by patent-landscape standards — a long tail of single- and few-filing entrants sits behind the leaders.
Volume has cooled from its 2019 peak
Filings peaked at 939 in 2019 and the complete 2021-2024 window shows a 46% drop. That pullback reads as claim space filling in on core formulation approaches rather than the field going quiet — the most recent two years are still under-reported due to publication lag.
Formulation chemistry crowds out delivery hardware
A61K medicinal-preparation classifications sit on four out of five records, while A61M device classifications and G01N testing/analysis classifications each stay under 4%. That gap points to where claim density is light relative to how central those functions are to actually getting a dose through the gut.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to oral drug delivery patent landscape, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Genentech Inc | AC Immune SA | 291 |
| Genentech Inc | Xenon Pharmaceuticals Inc | 176 |
| Leadiant Biosciences | Janssen Biotech Inc | 87 |
| Auspex Pharmaceuticals Inc | SARSHAR SEPEHR | 65 |
| Auspex Pharmaceuticals Inc | GANT THOMAS G | 64 |
| Amgen Inc | U3 Pharma GmbH | 58 |
| Genentech Inc | Arvinas Operations Inc | 53 |
| Amgen Inc | Daiichi Sankyo Europe GmbH | 52 |
The strongest co-assignee pairing in this dataset links two biologics-focused filers at 291 shared records, well ahead of the next strongest pairing — a sign of a small number of tight R&D partnerships rather than broad industry-wide co-filing.
Who is filing, and where the gaps sit
The ranking covers 100 companies across the full 20,627-record corpus. Momentum varies sharply even among the largest historical filers, which matters more for where to watch next than the raw totals do.
The top filer's momentum has flattened
The leading assignee by volume shows 0 filings in the latest year and a -100% year-on-year change, consistent with a company that built out its core formulation portfolio earlier in the window rather than one still actively expanding it.
A smaller filer is accelerating from a low base
CytomX Therapeutics shows +500% year-on-year growth into the latest year, albeit off a small base of 6 filings — the kind of signal worth tracking even though it does not yet register in the overall top-5 concentration.
Most of the field sits outside the top 10
The ten largest filers combined reach 4,720 records, or 22.9% of the corpus — meaning more than three-quarters of all records come from entities outside that group. That is a wide base of activity rather than a field cornered by a handful of players.
| Assignee | Recent year | YoY |
|---|---|---|
| CytomX Therapeutics | 6 | +500% |
| NovImmune SA | 1 | -75% |
| Leadiant Biosciences | 1 | -67% |
| Amgen Inc | 0 | — |
| Genentech Inc | 0 | -100% |
| Laboratorios del Dr Esteve SA | 0 | — |
| F Hoffmann-La Roche & Co AG | 0 | — |
| AC Immune SA | 0 | — |
Where to take this next
The dataset points to specific follow-up questions rather than a single conclusion — the answers differ depending on whether you're clearing a formulation, tracking a competitor, or scoping a new filing.
Map freedom-to-operate around a specific coating or release mechanism
The most-cited records cluster around osmotic and pH-triggered release systems; a targeted search against your specific mechanism will surface the live claims that this landscape view aggregates.
Run a freedom-to-operate searchTrack momentum among the smaller, fast-moving filers
Year-on-year swings among filers below the top 5 are large in percentage terms even on small bases, and that is where competitive shifts tend to show up before they reach the leaderboard.
Monitor assignee momentumScope a filing into the thinner device and testing classes
A61M and G01N carry noticeably less density than the formulation classes, which may reflect genuine white space or simply a different filing strategy worth checking before drafting claims.
Explore the class-level detailCommon questions on the oral drug delivery patent landscape
The leading assignee in this dataset holds 820 records, but that is well short of controlling the field: the top 5 assignees combined account for only 15.0% of the 20,627 records in scope. That means most of the patent activity in oral drug delivery comes from a long tail of smaller filers rather than a handful of dominant companies. Anyone scoping freedom-to-operate should search broadly rather than assuming a small set of large portfolios covers the risk.
Filings peaked in 2019 at 939 records and the complete 2021-to-2024 window shows a 46% decline, from 772 down to 414. However, 2025 and 2026 figures in any dataset like this are understated because publication typically lags filing by around 18 months, so the most recent years should not yet be read as confirmed decline. The safest read is that the field cooled off its 2019 peak through 2024, with the most current trend still filling in.
Medicinal-preparation claims under IPC class A61K appear on 80.8% of the 20,627 records, making formulation chemistry the dominant claim category by a wide margin. Therapeutic-activity classifications (A61P) follow at 38.5%, with heterocyclic compounds and peptide/protein chemistry each appearing on roughly 19% of records. Device-oriented classes like A61M sit much lower, at 3.2%, indicating that the bulk of patent activity centres on what is in the dose rather than the hardware that delivers it.
The class-level data shows device hardware (A61M, 3.2% of records) and material analysis/testing methods (G01N, 3.5%) carry noticeably less claim density than formulation-focused classes, despite being essential to commercialising controlled-release and biologic oral products. Sub-areas like gut-permeation enhancer formulations and enteric-coating breakdown timing show up as comparatively thin relative to their practical importance. That does not guarantee an easy filing, but it flags areas where a targeted search is more likely to find open claim space than in the crowded formulation classes.
US20080213381A1, assigned to Sun Pharma Advanced Research Company Limited and published in 2008, claims a coated-tablet system with an active-ingredient core and a coating combining a water-insoluble polymer with a pH-dependent polymer, timed to break down after a predetermined delay. It is a specific delayed-release coating architecture, not a blanket claim over enteric coatings generally, so work using different polymer chemistries or triggering mechanisms sits outside its literal scope. Anyone designing a similar delayed-release tablet should check this filing's claim language directly rather than assume it only covers the general concept.
Research Oral Drug Delivery Patent Landscape in depth with Eureka
Go past this page: query the whole oral drug delivery patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.